Moderna (NASDAQ:MRNA) reached a global settlement with Arbutus and Genevant resolving litigation tied to Spikevax and related mRNA assets. Moderna will pay a $950 million lump sum in Q3 2026 and may pay up to an additional $1.3 billion depending on a Federal Circuit ruling.
The company will record a $950 million charge in Q1 2026, expects no accrual for contingent payment, and forecasts year-end 2026 cash of $4.5–$5.0 billion with total liquidity of $5.4–$5.9 billion.
Loading...
Loading translation...
Positive
Lump-sum settlement of $950 million limits near-term litigation exposure
No future royalties owed across Moderna infectious-disease portfolio
Projected 2026 year-end cash of $4.5–$5.0 billion
Total projected liquidity of $5.4–$5.9 billion including credit access
Negative
Recorded charge of $950 million expected in Q1 2026
Potential additional payment up to $1.3 billion contingent on Federal Circuit outcome
No accrual recorded for contingent payment; outcome remains uncertain
News Market Reaction – MRNA
+15.99%1.8x vol
125 alerts
+15.99%News Effect
+17.4%Peak Tracked
-6.0%Trough Tracked
+$3.24BValuation Impact
$23.51BMarket Cap
1.8xRel. Volume
On the day this news was published, MRNA gained 15.99%, reflecting a significant positive market reaction.
Argus tracked a peak move of +17.4% during that session.
Argus tracked a trough of -6.0% from its starting point during tracking.
Our momentum scanner triggered 125 alerts that day, indicating very high trading interest and price volatility.
This price movement added approximately $3.24B to the company's valuation, bringing the market cap to $23.51B at that time.
Trading volume was above average at 1.8x the daily average, suggesting increased trading activity.
Settlement payment:$950 millionPotential additional payment:Up to $1.3 billionSettlement charge:$950 million+5 more
8 metrics
Settlement payment$950 millionLump-sum payment in Q3 2026 to resolve global litigation
Potential additional paymentUp to $1.3 billionContingent on Federal Circuit decision under Section 1498
Settlement charge$950 millionCharge expected in Q1 2026 related to settlement
Year-end 2026 cash$4.5–$5.0 billionProjected cash and cash equivalents at end of 2026
Credit facility capacityUp to $900 millionRemaining access under existing credit facility
Total 2026 liquidity$5.4–$5.9 billionProjected liquidity at end of 2026 including credit facility
Breakeven target year2028Company aim to drive toward breakeven
Settlement timingQ3 2026Timing of the $950 million lump-sum payment
Market Reality Check
Price:$45.37Vol:Volume 9,372,805 is sligh...
normal vol
$45.37Last Close
VolumeVolume 9,372,805 is slightly below the 20-day average of 10,295,667 (relative volume 0.91x).normal
TechnicalPrice at $52.85 is trading above the 200-day MA of $30.56 and 4.27% below the 52-week high.
Peers on Argus
MRNA was down 1.35% while key biotech peers were mixed: ROIV -2.19%, HALO +1.16%...
MRNA was down 1.35% while key biotech peers were mixed: ROIV -2.19%, HALO +1.16%, MDGL +1.25%, VRNA +0.06%, BPMC +0.09%. No peers appeared in the momentum scanner, indicating a stock-specific move rather than a sector-wide reaction.
Q4 and FY 2025 results with cost cuts, 2026 growth plan, and pipeline updates.
Pattern Detected
Recent news with positive regulatory or business developments has typically seen aligned positive price reactions, suggesting the stock has responded constructively to favorable catalysts.
Recent Company History
Over the past weeks, Moderna reported several constructive updates. On Feb 13, 2026, Q4 and FY 2025 results showed reduced losses and strong cash, with the stock up 5.29%. Subsequent regulatory milestones for mNEXSPIKE, mRNA‑1010, and mCOMBRIAX in Europe and the U.S. drove gains of 4.03%, 6.08%, and 3.6% between Feb 17–27. An investor conference announcement on Feb 19 added another 6.65%. Today’s litigation settlement fits into this pattern of de‑risking and portfolio clarification.
Market Pulse Summary
The stock surged +16.0% in the session following this news. A strong positive reaction aligns with t...
Analysis
The stock surged +16.0% in the session following this news. A strong positive reaction aligns with the removal of a longstanding litigation overhang through a one-time $950 million settlement and clearer visibility on potential additional exposure of up to $1.3 billion. The company also projected year-end 2026 liquidity of $5.4–$5.9 billion, which may have reassured investors about balance sheet strength. However, high expectations for cash preservation and future growth could make sentiment sensitive to execution and any adverse legal outcomes.
Key Terms
section 1498, federal circuit, supreme court, government-contractor immunity, +1 more
5 terms
section 1498regulatory
"District Court's Section 1498 decision to be appealed to the Federal Circuit Court of Appeals"
Section 1498 is a U.S. federal law that lets the government, or parties it authorizes, use or make a patented invention without the patent owner’s prior permission, while requiring the government to pay monetary compensation through a special claims process. For investors, it matters because it can remove or shorten a company’s exclusive control over a product—for example allowing broader manufacturing or sales—potentially reducing future revenue, altering competitive dynamics, and affecting valuation; think of it as the government borrowing a company’s tool and promising to settle the bill later.
federal circuitregulatory
"appealed to the Federal Circuit Court of Appeals with potential additional payment contingent"
The Federal Circuit is a specialized U.S. appeals court that handles nationwide cases in specific areas like patents, government contracts, trade and certain federal claims. For investors it matters because its rulings can change whether companies can protect or monetize inventions, win or lose large contract disputes, or face financial liabilities — similar to a single referee whose calls can reshape the score in many related games across industries.
supreme courtregulatory
"should Moderna ultimately prevail through further proceedings - whether en banc, at the Supreme Court"
The supreme court is the highest judicial body in a jurisdiction that issues final, binding decisions on legal disputes, constitutional questions, and how laws should be interpreted. Its rulings can change rules that govern businesses, alter regulatory responsibilities, affect corporate liabilities and shareholder rights, and resolve market uncertainty — like a final referee whose call can reshape the playing field for entire industries and influence investor outlooks.
government-contractor immunityregulatory
"argue its government-contractor immunity defense limits its liability under federal statute"
A legal protection that shields companies from certain lawsuits or liabilities for work performed under government contracts or explicit government direction. Think of it like a safety net a subcontractor gets when carrying out instructions from a government principal: if the firm followed the government’s orders, some claims may be blocked or redirected to the government. For investors this matters because it reduces a contractor’s legal and financial risk, affecting potential losses, insurance costs, and the company’s valuation.
credit facilityfinancial
"retains access to up to $900 million under its existing credit facility"
A credit facility is a flexible loan arrangement that allows a borrower to access funds up to a set limit whenever needed, similar to a company having an overdraft option on a bank account. It matters to investors because it indicates how easily a business can secure cash when required, affecting its ability to manage expenses, invest, or respond to financial challenges.
AI-generated analysis. Not financial advice.
Moderna to pay $950 million with no future royalties to resolve all global litigation; corresponding charge expected in Q1 2026
District Court's Section 1498 decision to be appealed to the Federal Circuit Court of Appeals with potential additional payment contingent on the outcome; no accrual recorded for potential additional payment as loss is not considered probable
2026 year-end cash and cash equivalents now expected to be in the range of $4.5 - $5.0 billion
CAMBRIDGE, MA / ACCESS Newswire / March 3, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that it has entered into a settlement agreement with Arbutus Biopharma Corporation and Genevant Sciences GmbH resolving all litigation worldwide, including between the parties in the U.S. District Court for the District of Delaware.
The settlement resolves all worldwide Arbutus/Genevant litigation related to Spikevax® and mRESVIA® and provides certainty going forward for Moderna's full infectious disease portfolio, including mNEXSPIKE®, mCOMBRIAX® and its future vaccine pipeline, with no future royalties owed. Under the terms of the agreement, Moderna will make a lump sum payment of $950 million in the third quarter of 2026.
Under the agreement, Moderna will appeal to the Federal Circuit to argue its government-contractor immunity defense limits its liability under federal statute, 28 U.S.C. § 1498. If Moderna ultimately prevails on that issue, no further payments will be due. If, however, the Federal Circuit affirms liability under Section 1498, Moderna has agreed to make an additional payment of up to $1.3 billion within 90 days of that decision, depending on the scope of the decision. Thereafter, should Moderna ultimately prevail through further proceedings - whether en banc, at the Supreme Court, or on remand to the district court - Arbutus/Genevant will refund the full payment plus interest.
Moderna expects to record a charge of $950 million in the first quarter of 2026 related to the settlement payment. The Company has concluded that a loss related to the pending Section 1498 proceeding is not probable, and accordingly, expects no charge to be recorded.
As a result of the settlement, Moderna expects to end 2026 with $4.5 to $5.0 billion in cash and cash equivalents, and retains access to up to $900 million under its existing credit facility. The total projected liquidity available to the Company at the end of 2026 will be $5.4 to $5.9 billion.
"Resolving this legacy matter from our pandemic response removes uncertainty and allows us to turn our full focus to Moderna's exciting near-term future," said Stéphane Bancel, Chief Executive Officer of Moderna. "In 2026, we will return to revenue growth and end the year with a strong balance sheet, with more than $5 billion in liquidity, as we drive toward breakeven in 2028. This year we also expect the approval of our flu plus COVID combination and standalone flu vaccines, and several highly anticipated therapeutic clinical trial results in cancer and in rare disease. We remain focused on driving growth by delivering transformative medicines to patients."
Moderna continues to actively enforce and defend its intellectual property portfolio, including affirmative claims against other market participants such as Pfizer and BioNTech. The Company continues to believe that assets will exceed liabilities across its portfolio of intellectual property litigation.
About Moderna
Moderna is a pioneer and leader in the field of mRNA medicine. Through the advancement of its technology platform, Moderna is reimagining how medicines are made to transform how we treat and prevent diseases. Since its founding, Moderna's mRNA platform has enabled the development of vaccines and therapeutics across infectious diseases, cancer, rare diseases and more.
With a global team and a unique culture, driven by the company's values and mindsets, Moderna's mission is to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X, Facebook, Instagram, YouTube and LinkedIn.
Spikevax®, mRESVIA®, mNEXSPIKE® and mCOMBRIAX® are registered trademarks of Moderna.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: Moderna's settlement with Arbutus/Genevant; Moderna's appeal to the Federal Circuit of the District Court's Section 1498 decision, including potential outcomes; potential additional payment contingent on the outcome of the appeal; Moderna's expected 2026 year-end cash balance and total projected liquidity; certainty for Moderna's full infectious disease portfolio; the expected $950 million charge in the first quarter of 2026; Moderna's credit facility; Moderna's expected revenue growth in 2026; Moderna's expected breakeven in 2028; expected approval of Moderna's flu plus COVID combination and standalone flu vaccines this year; anticipated therapeutic clinical trial results in cancer and rare disease; Moderna's ongoing intellectual property litigation; and Moderna's belief that assets will exceed liabilities across its portfolio of intellectual property litigation. In some cases, forward-looking statements can be identified by terminology such as "will," "may," "should," "could," "expects," "intends," "plans," "aims," "anticipates," "believes," "estimates," "predicts," "potential," "continue," or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading "Risk Factors" in Moderna's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the U.S. Securities and Exchange Commission (SEC), and in subsequent filings made by Moderna with the SEC, which are available on the SEC's website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date of this press release.
How much will Moderna (MRNA) pay to settle the Arbutus/Genevant litigation?
Moderna will pay a lump sum of $950 million in Q3 2026. According to the company, an additional contingent payment up to $1.3 billion could be due depending on the Federal Circuit decision scope.
Will Moderna (MRNA) owe future royalties after the settlement with Arbutus/Genevant?
No, the settlement eliminates future royalties on the covered assets. According to the company, the agreement resolves worldwide claims including Spikevax and related mRNA products with no royalties owed going forward.
How will the settlement affect Moderna's 2026 cash and liquidity guidance (MRNA)?
Moderna expects year-end 2026 cash of $4.5–$5.0 billion and total liquidity of $5.4–$5.9 billion. According to the company, this includes access to up to $900 million under its credit facility.
Will Moderna (MRNA) record a charge for the Arbutus/Genevant settlement and when?
Yes, Moderna expects to record a $950 million charge in Q1 2026 related to the settlement payment. According to the company, no accrual was recorded for any contingent additional payment.
Could Moderna (MRNA) owe more than $950 million after the Federal Circuit appeal?
Potentially yes; Moderna agreed to pay up to an additional $1.3 billion if the Federal Circuit affirms liability under Section 1498. According to the company, refunds plus interest apply if Moderna later prevails.
